I. Project Outline
Alprostadil injection is biochemical drugs for the treatment of myocardial infarction, thrombosis, coronary heart disease, angina pectoris, arteriosclerosis and other cardiovascular and cerebrovascular disease, whose effects are better than other cardiovascular drugs. It has the function of expanding blood vessels, reducing the cardiac load, as well as natriuresis, diuresis, cardiac, improving coronary circulation, myocardial preservation, improving microcirculation, stabilizing membrane, removing non-protein nitrogen to protect kidney function, clearing immune complex, inhibiting platelet aggregation and other effects. Other general cardiovascular drugs are lack of these functions. Alprostadil market developed rapidly. Since 2000, it has become the best selling drug in the sample hospitals’ medication of China's major cities, and is one of the 41 fastest growing varieties. Technical features of this project are: the manufacturing technique of this project uses the most advanced equipment in China with national-leading technical level. It also adopts High Performance Liquid Chromatography, achieving quantitative control of effective components, so as to improve the standards of product quality and ensure product quality more stable, reliable and safe, without any infusion reactions. The products researched and manufactured by 15 domestic existing companies have infusion reactions; one is infusion reactions, one is acute lymphangitis. Another is pain.
II.Construction Scale and Project Plan
Annual output of 120 million alprostadil injection freeze-dried powder. Product plan: alprostadil for injection. The product ingredients are alprostadil (20H3405), with 85.0%-120.0% of the labeled amount. It is a western medicine and prescription drug, and formulation of the freeze-dried powder. The product specification content is 0.1 mg, and the main functions are to treat arteriosclerosis obliterans, thromboangiitis obliterans, cerebral arteriosclerosis, cerebral infarction, heart failure, angina, and central retinal vein thrombosis, diabetes, nephritis, acute pancreatitis, and also to treat serious illness, hepatitis A,B,C, inhibition of patients with duodenum, gastric acid secretion, and can also be used to terminate early pregnancy and treatment of functional impotence. The total construction area covers 9200 square meters with the main construction contents of injection workshop and warehouse, complex building (including testing rooms, offices, dining-rooms, dormitories), power station (including substations, boiler room, water supply stations, sewage stations, service station), animal housing and guard room.
III. Market Analysis and Economic Benefit Forecast
The project will produce 120 million alprostadil freeze-dried powder. Annual output value: 1.14 billion, sales income : 780 million Yuan, value added tax: 91.7354 million Yuan, sales tax and extra changes: 11.0083 million Yuan, net profit: 67.2 million Yuan, the internal rate of return: 74.15% (before income tax), investment payback period: 3.13 years, ratio of investment: 55.2%.
IV. Total Project Investment and Financing Arrangement
The total project investment is 121.54 million Yuan, of which the capital amount is 80 million Yuan. Sources of capital: 42 million Yuan of the capital owned by enterprises and 38 million Yuan of foreign investment.
V. Cooperation Ways
Joint venture
VI. Foreign Investment and Constitution
Capital.
VII. Project Construction Venue
Liuhe County, Tonghua City
VIII. Project Progress
The project record, planning, land, environmental impact assessment approval process has been completed. Research has been done. Construction site is in the original area and can start the timely construction. Registration documents were issued by SFDA with State Drug Approval Number : H20084246.
IX. Outline of Project Organizer
1. Enterprise Name: Ji Lin Tianqiang Pharmaceutical Co., Ltd.
Legal Address: 518 Station Road of Liuhe Town in Liuhe County
Legal Representative: Yan Zhonghui
2.Enterprise Profile: Ji Lin Tianqiang Pharmaceutical Co., Ltd. is a private enterprise, established in September 1999; registered capital: 12.06 million Yuan, total assets: 96 million Yuan, assets liabilities ratio: 60%, area of factory site: 55,000 square meters, construction area: 26,000 square meters, existing staff and employee: 350, including 45 senior and intermediate-level engineers and technicians, main equipment: 302 sets, the annual production capacity: 500 tons of Chinese and Western medicine, bank credit rating: AAA grade, output value in 2008: 45 million Yuan, sales income: 42 million Yuan, taxes paid: 3.7 million Yuan, profit: 3.58 million Yuan.
X. Contact methods:
Postal Code: 135300
Contact Person: Yan Zhonghui
Tel: 0086-435-7321066
Fax: 0086-435-7333322
Mobile Phone: 13904455368
E-mail: tqyzh@jltq.com
